Tag Archive


#FuckAlzheimers alzheimers alzheimers search engine collective cure data database dementia directory disease facebook feed find a cure Fuck Alzheimers g8 mission news research rss search search engine. team twitter website

How do we recall the past? New mechanism revealed">How do we recall the past? New mechanism revealed

A brain study in rats that explored different environments reveals that the anterior cingulate cortex drives the hippocampus in long-term memory recall. Read & Research Alzheimer’s More

Alzheimer's: Brain changes may occur 34 years before symptoms">Alzheimer's: Brain changes may occur 34 years before symptoms

New research finds that some Alzheimer’s-related biomarkers in the brain change as early as 34 years before the onset of visible symptoms. Read & Research Alzheimer’s More

Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease">Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease

The longitudinal trajectories of functional brain dynamics and the impact of genetic risk factors in individuals at risk for Alzheimer’s disease are poorly understood. Read & Research Alzheimer’s More

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease">Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer’s disease clinical trials and management. Read & Research Alzheimer’s More

Dementia: New WHO prevention guidelines evaluate 12 risk factors">Dementia: New WHO prevention guidelines evaluate 12 risk factors

The WHO have recently released a new set of guidelines around strategies for dementia prevention, in which they evaluate potential interventions. Read & Research Alzheimer’s More

Virtual reality may help stimulate memory in people with dementia">Virtual reality may help stimulate memory in people with dementia

According to a recent study, virtual reality might provide a useful tool for treating dementia. Among other things, it may help improve memory. Read & Research Alzheimer’s More

Novel Alzheimer's drug passes first phase of human testing">Novel Alzheimer's drug passes first phase of human testing

A drug that tackles toxic protein buildup in Alzheimer’s disease in a novel way has passed phase 1 of clinical trials, which tests safety in humans. Read & Research Alzheimer’s More

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology">Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology

18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. Read & Research Alzheimer’s More

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint">Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint

Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression. Read & Research Alzheimer’s More

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort">Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

A critical and as-yet unmet need in Alzheimer’s disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Read & Research Alzheimer’s More

Alzheimer's: How light therapy could protect the brain">Alzheimer's: How light therapy could protect the brain

A study uncovers the neuron and immune cell changes that explain why light therapy can reduce toxic brain proteins in mouse models of Alzheimer’s disease. Read & Research Alzheimer’s More

The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community">The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community

In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer’s Read & Research Alzheimer’s More

Could a cell phone game detect who is at risk of Alzheimer's?">Could a cell phone game detect who is at risk of Alzheimer's?

According to a new study, a cell phone game called ‘Sea Hero Quest’ could assist researchers in identifying people who are more at risk of Alzheimer’s. Read & Research Alzheimer’s More

Erratum to “Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice” [Alzheimer’s & Dementia 2016;12:1273-87.]">Erratum to “Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice” [Alzheimer’s & Dementia 2016;12:1273-87.]

In the article “Kallikrein-8 inhibition attenuates Alzheimer’s disease pathology in mice,” published in the December 2016 issue of Alzheimer’s & Dementia, the authors would like to amend the Acknowledgments section to include the contributions of Constanze Roggendorf, Anthony Stang, and Ilkay Yavuz. Read & Research Alzheimer’s More

Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa">Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa

Primary age-related tauopathy (PART) is characterized by the presence of neurofibrillary tangles and absent-minimal β-amyloid deposition. Transactive response DNA-binding protein of 43 kDa (TDP-43), a third protein, has recently garnished a lot of attention in Alzheimer’s disease where it is associated with memory loss and amygdala and hippocampal atrophy. We aimed Read & Research Alzheimer’s More

Urate and risk of Alzheimer's disease and vascular dementia: A population-based study">Urate and risk of Alzheimer's disease and vascular dementia: A population-based study

Low serum urate (sU) has been suggested to increase the risk of dementia since a reduction might impair antioxidant capacity. On the other hand, high sU is associated with increased cardiovascular risk which might increase the risk of dementia, especially for vascular dementia. Read & Research Alzheimer’s More

Experts draft guidelines for Alzheimer's-like condition">Experts draft guidelines for Alzheimer's-like condition

Experts have defined an under-recognized, newly named condition that mimics Alzheimer’s disease and propose guidelines for diagnosing and researching it. Read & Research Alzheimer’s More

Inflammatory biomarkers in Alzheimer's disease plasma">Inflammatory biomarkers in Alzheimer's disease plasma

Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Read & Research Alzheimer’s More

Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials">Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials

Multidomain interventions, targeting multiple risk factors simultaneously, could be effective dementia prevention strategies, but may be burdensome and not universally acceptable. Read & Research Alzheimer’s More

Scientists confirm blood test could track Alzheimer's disease">Scientists confirm blood test could track Alzheimer's disease

Data from up to 11 years of blood samples confirm neurofilament light protein as a potential noninvasive marker of Alzheimer’s disease progression. Read & Research Alzheimer’s More

Mitigating stigma of Alzheimer's disease dementia among Chinese Americans">Mitigating stigma of Alzheimer's disease dementia among Chinese Americans

We read with great interest the article by Stites et al. [1] and commend the authors for analyzing stigma of dementia among 317 adults from the US general public. Their study showed that 55% respondents expected a person with dementia to be discriminated by his/her employers, and approximately 46% respondents expected Read & Research Alzheimer’s More

Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations">Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations

Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. It is generally accepted that endothelial dysfunction, including blood-brain barrier (BBB) failure, is pivotal in the pathophysiology. Recent years have seen increasing use Read & Research Alzheimer’s More

Can a blood pressure drug protect the brain from Parkinson's?">Can a blood pressure drug protect the brain from Parkinson's?

At blood levels that are typical in humans, an approved high blood pressure drug was able to clear toxic proteins of Parkinson’s disease from mouse brains. Read & Research Alzheimer’s More

A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment">A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment

Unlike for glucose, uptake of the brain’s main alternative fuel, ketones, remains normal in mild cognitive impairment (MCI). Ketogenic medium chain triglycerides (kMCTs) could improve cognition in MCI by providing the brain with more fuel. Read & Research Alzheimer’s More

Aaron Klug and the study of Alzheimer's disease">Aaron Klug and the study of Alzheimer's disease

Aaron Klug, who died on November 20, 2018, was a giant of molecular biology [1–3]. He was also a major figure in the study of dementia, especially Alzheimer’s disease. In 1982, Aaron was the sole recipient of the Nobel Prize in Chemistry “for his development of crystallographic electron microscopy and Read & Research Alzheimer’s More

Alzheimer's: Synthetic protein blocks toxic beta-amyloid">Alzheimer's: Synthetic protein blocks toxic beta-amyloid

Scientists have designed a protein that folds into alpha sheets that can block toxic beta-amyloid in brain cells before it forms into large clumps. Read & Research Alzheimer’s More

Dementia: Paradigm shifting into high gear">Dementia: Paradigm shifting into high gear

Redressing the rising threat of dementia demands not only an increase, but a diversification of efforts. We need new approaches, trials, and partners. We cannot afford to continue to only round up the usual suspects, β amyloid, and tau and try to stop them with a single drug “silver bullet”. Read & Research Alzheimer’s More

Erratum to “Validation of a simple severity scale for assessing ARIA-E” [Alzheimer’s & Dementia 2017;13:P253-4.]">Erratum to “Validation of a simple severity scale for assessing ARIA-E” [Alzheimer’s & Dementia 2017;13:P253-4.]

In the abstract “Validation of a simple severity scale for assessing ARIA-E,” published in the July 2017 Supplement issue of Alzheimer’s & Dementia, the values in the first column of Table 1 were incorrectly listed as “mm” instead of “cm.” The corrected table is below. Read & Research Alzheimer’s More

Syncing brain waves may fight age-related memory problems">Syncing brain waves may fight age-related memory problems

Working memory tends to decline with age, and this problem is characterized by poor synchronicity between brain regions. Can researchers ‘fix’ this issue? Read & Research Alzheimer’s More